JTO Clinical and Research Reports

Dacomitinib With or Without Dose Titration in Treatment-Naive Advanced EGFR-Mutated NSCLC — Primary Analysis of the ATORG-003 Phase 2 Trial

Pub Date : 2026-10-01 DOI: 10.1016/j.jtocrr.2026.101027 Aaron C. Tan M.B.B.S., PhD, FRACP, Tae Min Kim MD, Siqin Zhou MSc, Yueh Ni Lim M.B.B.S., Gwo Fuang Ho M.B.B.S., Lye Mun Tho M.B.B.S., Thanyanan Baisamut MD, Naiyarat Prasongsook MD, Suee Lee MD, Sze Huey Tan PhD, Dong-Wan Kim MD, Tony Mok MD, Daniel S.W. Tan M.B.B.S., Herbert H. Loong M.B.B.S.

Garsorasib (D-1553) in Combination With Pembrolizumab and Chemotherapy for First-Line Metastatic NSCLC With KRAS G12C Mutation: Results of a Phase 1b Study

Pub Date : 2026-10-01 DOI: 10.1016/j.jtocrr.2026.101037 Dong Yan MD, Chaoying Liu MD, Xingya Li MD, Melissa Moore MBBS, PhD, Ruihua Xu MD, Rachel E. Sanborn MD, Shirish M. Gadgeel MD, Michael Millward MD, Zhe Shi MD, Yaolin Wang MD, Kathryn Stazzone BS, Michael J. Chisamore PhD, Ling Zhang MD, PhD

Integration of Histologic Pattern Classifiers and Graph Convolutional Networks for Prognostic Prediction in Lung Adenocarcinoma

Pub Date : 2026-09-01 DOI: 10.1016/j.jtocrr.2026.101017 Yi-Chen Yeh MD, PhD, Wei-Hsiang Yu MS, Min-Shu Hsieh MD, PhD, Fu-Pang Chang MD, Lei-Chi Wang MD, PhD, Chao-Wen Lu MD, Bojan Karlaš PhD, Kun-Hsing Yu MD, PhD, Yu-Chung Wu MD, Jin-Shing Chen MD, PhD, Ming-Sound Tsao MD, PhD, Chao-Yuan Yeh MD, Teh-Ying Chou MD, PhD